Intro Paragraph

Approved Substudies

Substudies that have been approved by the Global Trial Steering Committee (GSTC)

SNAPPER

SNAP Prospective Evaluation of Renal effects

icon-benefit
Australia
icon-benefit
Active Substudy
icon-benefit
Recruiting

SNOOPY

Staphylococcus aureus Network: ultrasound for diagnosis of endovascular disease in Paediatrics and Youth

icon-benefit
Australia, All Interested
icon-benefit
Active Substudy
icon-benefit
Recruiting

CAESAR – Study 1

Relation between cefazolin and flucloxacillin exposure and outcome

icon-benefit
The Netherlands
icon-benefit
Active Substudy
icon-benefit
Recruiting

CAESAR – Study 2

Difference in the emergence of resistant pathogens between cefazolin and flucloxacillin

icon-benefit
The Netherlands
icon-benefit
Active Substudy
icon-benefit
Recruiting

SIMPLY SNAP

Evaluating the impact of a SIMPlified Layered consent process versus a conventional informed consent form on recruitment of potential participants to a large platform clinical trial: a pragmatic nested randomized controlled trial

icon-benefit
Canada and Australia
icon-benefit
Active Substudy
icon-benefit
Recruiting

O-SNAP

Optimizing antibiotic dosing in the Staphylococcus aureus Network Adaptive Platform trial

icon-benefit
Australia
icon-benefit
Active Substudy
icon-benefit
Recruiting

CERT-SNAP

Combination Cefazolin with Ertapenem for methicillin-susceptible Staphylococcus aureus bacteremia.

icon-benefit
Canada
icon-benefit
Active Substudy
icon-benefit
Recruiting

DAPTO-SNAP

Daptomycin vs. Vancomycin for the Treatment of MRSA bacteremia

icon-benefit
All Interested
icon-benefit
Active Substudy
icon-benefit

Bacteriuria

Significance of S. aureus bacteriuria in patients hospitalized with S. aureus bacteremia

icon-benefit
Any Interested
icon-benefit
Active Substudy
icon-benefit

Stats-GWAS

A statistical genomics framework to improve prediction of treatment outcomes of Staphylococcus aureus bacteraemia (SAB)

icon-benefit
Any interested
icon-benefit
Active Substudy
icon-benefit

PR-O-SNAP

PK/PD of oral beta-lactam with and without probenecid for treatment of Staphylococcus aureus bacteraemia.

icon-benefit
New Zealand
icon-benefit
Active Substudy
icon-benefit

Intro Paragraph

Substudies in Progress

Substudies that are in the process of obtaining approval

SABSI

Profiling the genetic and epigenetic determinants that predispose to severe manifestations of Staphylococcus aureus bacteremia

icon-benefit
All Interested
icon-benefit
Substudy in Progress

cfDNA

Cell-free DNA is a Versatile Analyte to Monitor Complications and Guide Treatment Duration in Staphylococcus aureus Bacteremia

icon-benefit
Any interested
icon-benefit
Substudy in Progress

SABSI-Outcomes

Derivation and Validation of Phenotypes of Staphylococcus aureus bloodstream infection, with Correlation with Outcome.

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

SNAP-SEQ

Pilot study for real-time sequencing of Staphylococcus aureus bloodstream isolates

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

PENFAST

Using a validated penicillin allergy risk prediction tool (Pen-FAST) in patients with a low risk penicillin allergy 

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

Pharmacogenomics

 Immunopathogenesis and pharmacogenomics of severe antibiotic hypersensitivity 

icon-benefit
Australia
icon-benefit
Substudy in Progress

HRQOL

Using microdata to assess the impact of Staphylococcus aureus bacteremia

icon-benefit
New Zealand
icon-benefit
Substudy in Progress

Ceftrixione vs. Flucloxacillin

Ceftriaxone vs (Flu)cloxacillin for S. aureus bacteraemia

icon-benefit
Locations that use ceftriaxone
icon-benefit
Substudy in Progress

CDI

Outcomes of Staph aureus Infective endocarditis and cardiac device infections

icon-benefit
icon-benefit
Substudy in Progress

PWID Colonization

Staphylococcus aureus colonisation in people who inject drugs

icon-benefit
icon-benefit
Substudy in Progress

PWID PISA

Dalbavancin vs standard of care for people who inject drugs with Staphylococcus aureus bacteraemia: A pragmatic, multicentre, randomised, non-inferiority trial

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

SNAP-TIE

Targeting Inequities in Enrolment – an observational study evaluating socio-demographic predictors of participation in the SNAP trial (the SNAP-TIE study)

icon-benefit
Canada
icon-benefit
Substudy in Progress

TARGET Trial

Are trial treatment effects preserved in patients excluded from the trial? Comparison of cefazolin versus (flu)cloxacillin for MSSA bacteremia in the SNAP registry.

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

Adj Fosfomycin

Adjunctive fosfomycin therapy in patients with Staphylococcus aureus bloodstream infection at high risk of complications or relapse

icon-benefit
Europe
icon-benefit
Substudy in Progress

SABRE-phi

Staphylococcus aureus bacteraemia treated with phage therapy to improve outcomes (SABRE-Phi trial)

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

UK HE

SNAP UK Health Economics

icon-benefit
UK
icon-benefit
Substudy in Progress

C-Snap

C-SNAP: Evaluating the prevalence of vitamin C deficiency and plasma vitamin C level decay in a prospective sample of patients with Staphylococcus aureus bacteraemia enrolled in the SNAP trial

icon-benefit
Any Interested
icon-benefit
Substudy in Progress

SNAP Team

Co-ordinating Investigators

Meet the SNAP Team
Joshua Davis

Professor Joshua S Davis PhD, FRACP, MBBS (Hons), DTM&H, Grad Cert Pop Health. Infectious Diseases Physician and NHMRC Career Development Fellow at the University of Newcastle and the Menzies School of Health Research.

Steven Tong

Professor Steven YC Tong PhD, FRACP, MBBS (Hons), Grad Dip Epidemiol Biostats, Infectious Diseases Physician with the Victorian Infectious Diseases Service.

BACK TO TOP